Rationale for Using TAS-102 in Patients With Gastric Cancer

Hendrik-Tobias Arkenau, MD, PhD, executive medical director, executive medical director for Sarah Cannon Research Institute UK, discusses the rationale for using TAS-102 (trifluridine/tipiracil; Lonsurf) as a treatment for patients with colorectal and gastric cancers.

Arkenau emphasizes that gastric cancers are of the most common cancers worldwide and are related to both the third and fifth most common cancers. In recent phase II and III trials, TAS-102 has shown good clinical evidence in these patients, and particularly those who with either colorectal cancer or more than 2 lines of therapy.

These results appear for promising in gastric cancer. In further investigation of the drug, patients accepted to receive TAS-102 include those who have failed the standard of care therapy and at least 2 prior lines of therapy.